Part D Price Negotiation Provision In House Reform Bill Missing Its Teeth?
This article was originally published in The Pink Sheet Daily
Executive Summary
The provision, added during markup by the Energy and Commerce Committee, does not authorize HHS to establish a formulary. As a result, it may not be viewed as a cost saver, based on past CBO estimates of similar legislation.
You may also be interested in...
Health Reform Bill Picks Up Key Pharma Measures: Part D Price Negotiation, HHS Formulary For The Public Plan
Rx provisions added to House Energy and Commerce Committee-approved bill July 31.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
One Trial Plus Supportive Evidence Is Enough For Hospital-, Ventilator-Acquired Pneumonia Indication, Panel Says
Anti-Infective Drugs Advisory Committee members viewed one-trial as practical means of gaining efficacy data.